Physician profile
Joseph E Sandusky
NPI 1548547359
$5,522.05
in general payments reported to CMS, 2019-2025
39 companies · $635 in 2025
The $635 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,367 · 2022: $1,192 · 2023: $924 · 2024: $1,404 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $761.34 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $420.79 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $342.05 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $341.20 | 2021-2024 | Otezla, Repatha |
| Pfizer INC. | $318.18 | 2021-2025 | |
| Exact Sciences Corporation | $274.78 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $263.50 | 2021-2024 | |
| Lilly USA, LLC | $235.77 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Mylan Specialty L.P. | $201.57 | 2021-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $186.62 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $157.31 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $155.10 | 2021 | |
| Merck Sharp & Dohme LLC | $140.89 | 2021-2024 | Verquvo, Belsomra, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.34 | 2021-2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $139.26 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sandusky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.